II-01 Teijo Saari Significant changes in pharmacokinetics of sufentanil during target controlled infusion of sufentanil for cardiac anaesthesia. Wednesday 15:10-16:40 |
II-02 Muhammad Waqas Sadiq Oxymorphone PKPD relationship and blood-brain barrier transport studied with microdialysis Wednesday 15:10-16:40 |
II-03 Mark Sale Identification of optimal NONMEM models using a multi-objective genetic algorithm. Wednesday 15:10-16:40 |
II-04 Nikolaos Tsamandouras Mapping in vitro and in vivo derived CYP3A ontogeny function: A critical comparison between various ontogeny models Wednesday 15:10-16:40 |
II-05 Maria Luisa Sardu Biomarker-driven Models of Tumour Growth Inhibition in preclinical animal studies Wednesday 15:10-16:40 |
II-06 Andre Schäftlein Microdialysate-corrected mid-interval model versus microdialysate-based integral model - Population pharmacokinetics of levofloxacin in peripheral tissues Wednesday 15:10-16:40 |
II-07 Emilie Schindler PKPD-Modeling of Standard Uptake Value (SUV) in Gastro-Intestinal Stromal Tumors (GIST) patients treated with sunitinib Wednesday 15:10-16:40 |
II-08 Alessandro Schipani Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies Wednesday 15:10-16:40 |
II-09 Rik Schoemaker Modelling and simulation of spontaneously reported adverse events after administration of lacosamide Wednesday 15:10-16:40 |
II-10 Bernard Sebastien Impact of delayed effect in Concentration-QT analyses. Wednesday 15:10-16:40 |
II-11 Eric Sherer Three case studies of pharmacokinetic model building using a multi-objective genetic algorithm Wednesday 15:10-16:40 |
II-12 Kwang-Hee Shin Population Pharmacokinetics and Pharmacodynamics of Escitalopram in Healthy Volunteers Wednesday 15:10-16:40 |
II-13 Satoshi Shoji Population Pharmacokinetics/Pharmacodynamics of Ampicillin/Sulbactam in Patients with Moderate or Severe Community-Acquired Pneumonia Wednesday 15:10-16:40 |
II-14 Hanna Silber Baumann Population pharmacokinetics of cyclosporine A in cats Wednesday 15:10-16:40 |
II-15 Monica Simeoni Estimation of Remifentanil Metabolic Ratio Using a Mixture Model Wednesday 15:10-16:40 |
II-16 Nicolas Simon A joint PK/PD-PD model of levodopa in patients with Parkinson's disease: Motor effect and Movement disorder Wednesday 15:10-16:40 |
II-17 Jean Smeets Development of a mechanistic based model for neonatal Fc receptor recycling to design human serum albumin mutants with extended half-lives Wednesday 15:10-16:40 |
II-18 Nelleke Snelder Quantification of Antidepressant and Sedative Effect of Two NMDA Channel Blockers, AZD6765 and Ketamine, in an Animal Model of Depression Using Count Data Wednesday 15:10-16:40 |
II-19 Alexander Solms Using Population PBPK Modelling to interpret Population PK results exemplified for Levofloxacin in Plasma and Interstitial Fluid Wednesday 15:10-16:40 |
II-20 Hankil Son Development of a longitudinal model to describe the QT-time course in healthy volunteers given placebo and moxifloxacin Wednesday 15:10-16:40 |
II-21 Alexandre Sostelly Dose and dose schedule optimization of anticancer drugs Wednesday 15:10-16:40 |
II-22 Alexander Staab A Model-based Meta-analysis Comparison of the Effects of Linagliptin and Sitagliptin on HbA1c Levels in Patients with Type 2 Diabetes Mellitus Wednesday 15:10-16:40 |
II-23 David Stepensky Inter-patient variability of local vs. systemic effects of TNF-α-neutralizing antibodies in rheumatoid arthritis Wednesday 15:10-16:40 |
II-24 Jasper Stevens Nonlinear mixed effects evaluation of Hamilton Depression Rating Score following combination treatment of presynaptic- and postsynaptic glutamate receptor inhibitors in bipolar depression patients Wednesday 15:10-16:40 |
II-25 Elisabet Størset Population pharmacokinetics of tacrolimus to aid individualized dosing in kidney transplant recipients Wednesday 15:10-16:40 |
II-26 Fran Stringer A Novel Pharmacodynamic Modeling Approach to Determine Long Term Disease Progression Rates in Japanese Type 2 Diabetes Patients: Pioglitazone vs. Conventional Therapy Wednesday 15:10-16:40 |
II-28 Herbert Struemper Target-mediated clearance of ofatumumab: a tale of different disease states Wednesday 15:10-16:40 |
II-29 Elin Svensson Linear approximation methods for fast evaluation of random effects models Wednesday 15:10-16:40 |
II-30 Stina Syvänen P-glycoprotein alterations at the blood-brain barrier influences [11C]flumazenil brain concentrations but does not interfere with estimation of GABAA receptor density in a rodent model of epilepsy Wednesday 15:10-16:40 |
II-31 Takeshi Tajima Mechanism-based assessment on the pharmacodynamics of neuromuscular relaxants and general consideration for receptor blockers Wednesday 15:10-16:40 |
II-32 Daniel Tatosian Strategic comparator modeling and simulation to optimize dose selection for a dose-range finding study Wednesday 15:10-16:40 |
II-33 David Ternant A model predicting expected infliximab serum concentrations using only dose and time since last infusion Wednesday 15:10-16:40 |
II-34 Nadia Terranova Modelling of protozoa dynamics and drug effects in a murine model of malaria infection Wednesday 15:10-16:40 |
II-35 Hoai-Thu Thai Residual-based bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models with heteroscedastic error Wednesday 15:10-16:40 |
II-36 Kirstin Thelen Dynamically simulating the effect of food on gastric emptying using a detailed physiological model for gastrointestinal transit and absorption Wednesday 15:10-16:40 |
II-37 Mirjam Trame Evaluating the Influence of Different Covariates on Enoxaparin Pharmacokinetics in Neonates, Infants and Children Wednesday 15:10-16:40 |
II-38 Kellie Turner Adapting a Target-mediated Drug Disposition (TMDD) Model to Account for Delayed tmax Following IV Infusion of a Monoclonal Antibody Wednesday 15:10-16:40 |
II-39 Wanchana Ungphakorn Development of Sparse Sampling Study of Oral Ciprofloxacin for Severely Malnourished Children Wednesday 15:10-16:40 |
II-40 Pyry Välitalo Optimal design for a population pharmacokinetic study of oxycodone in preterm neonates, neonates and infants Wednesday 15:10-16:40 |
II-41 Marta Valle Population pharmacokinetics of rupatadine in children 2-11 years of age with allergic rhinitis Wednesday 15:10-16:40 |
II-42 Sven van Dijkman Characterisation of response and disease progression in paediatric epilepsy Wednesday 15:10-16:40 |
II-43 Coen van Hasselt Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab Wednesday 15:10-16:40 |
II-44 Charlotte van Kesteren Predictive performance of a busulfan pharmacokinetic-model in children and young adults from five international transplant centers: a study of varying doses, underlying diseases, ethnicities, body weights, ages and body mass indices Wednesday 15:10-16:40 |
II-45 Eline van Maanen A step-wise analysis of multiple biomarkers drives the development of a Semi-Mechanistic Comprehensive Model. Application to modulation of Amyloid-β. Wednesday 15:10-16:40 |
II-46 Nieves Velez de Mendizabal Discrete distribution models for relapsing-remitting dynamics observed in Multiple Sclerosis Wednesday 15:10-16:40 |
II-47 Anders Viberg Using modeling and simulation to evaluate placebo run-in for pain studies Wednesday 15:10-16:40 |
II-48 Marie Vigan Evaluation of estimation methods for repeated time to event models: application to analysis of bone events during treatment of Gaucher Disease. Wednesday 15:10-16:40 |
II-49 Nageshwar Budha Population Analysis of wet-AMD Disease Progression and The Therapeutic Effect of Ranibizumab Wednesday 15:10-16:40 |
II-50 Sandra Visser MModel-based meta analysis of -secretase inhibitor data; has A production inhibition been adequately tested as therapeutic approach in mild AD? Wednesday 15:10-16:40 |
II-51 Georgios Vlasakakis Landscape on technical and conceptual requirements in Drug/Disease Modelling & Simulation Wednesday 15:10-16:40 |
II-52 Max von Kleist PK-PD Modelling of the Reverse Transcriptase Inhibitor Tenofovir and Quantification of its Prophylactic Efficacy against HIV-1 Infection Wednesday 15:10-16:40 |
II-53 Carin Wallsten Quantification of the Drug Effect and Exploration of Mechanism of Action of Two NMDA Channel Blockers, AZD6765 and Ketamine, using Mouse EEG Data Wednesday 15:10-16:40 |
II-54 Bing Wang Population pharmacokinetics and pharmacodynamics of mavrilimumab in rheumatoid arthritis patients Wednesday 15:10-16:40 |
II-55 Chenguang Wang Scaling morphine across the human life-span using a bodyweight-dependent allometric exponent model Wednesday 15:10-16:40 |
II-56 Sebastian Weber Mixed effect modeling of neuronal cell differentiation kinetics from longitudinal phase-contrast imaging data Wednesday 15:10-16:40 |
II-57 Thomas Wendl A whole-body physiologically-based pharmacokinetic Model for ketoconazole in different species ready to be used to predict dynamic drug-drug-interactions Wednesday 15:10-16:40 |
II-58 Shelby Wilson The Enhancement of Tumor Vaccine Efficacy by Immunotherapy Wednesday 15:10-16:40 |
II-59 Gudrun Wuerthwein Population Pharmacokinetics of caspofungin in a phase II dose escalation study Wednesday 15:10-16:40 |
II-60 Wenyuan Xiong Pharmacokinetic interspecies extrapolation of a fully human mAb from animal to human Wednesday 15:10-16:40 |
II-61 Stefano Zamuner PK-PD modelling of aOSM in RA patient study including exploration of carrier protein effect. Wednesday 15:10-16:40 |
II-62 Stefan Zeiser Population PK Modeling of Dapivirine Released from Vaginal Rings Wednesday 15:10-16:40 |
II-63 Jianping Zhang Population Analysis of Tumor Growth Inhibition and Progression-Free Survival Following Lapatinib Treatment in Patients with Advanced/Metastatic Breast Cancer Wednesday 15:10-16:40 |
II-64 Chao Zhang Model-based evaluation of the pharmacokinetic differences between adults and children administered lopinavir and ritonavir in combination with rifampicin Wednesday 15:10-16:40 |
II-65 Wei Zhao Population pharmacokinetics and dosing optimization of vancomycin continuous infusion in neonates Wednesday 15:10-16:40 |
II-66 Kirill Zhudenkov Application of the SBTOOLBOX2 in drug discovery and development Wednesday 15:10-16:40 |
II-67 BELA PATEL Probability-Based Risk Assessment of QT Prolongation in Early Phase Drug Development Wednesday 15:10-16:40 |
II-68 Parviz Ghahramani Population Pharmacokinetic Model for Cariprazine and its Major Metabolites in Patients with Acute Exacerbation of Schizophrenia Wednesday 15:10-16:40 |